Skip to main content
. 2018 Dec 5;363:k4823. doi: 10.1136/bmj.k4823

Table 1.

Pooled relative sensitivity and specificity of high-risk human papillomavirus (hrHPV) assays based on signal amplification (SA) and polymerase chain reaction (PCR) on self samples versus clinician samples

Assay Outcome No of studies Ratio (95% CI)
Sensitivity Specificity Test positivity PPV
SA CIN2+ 23 0.85 (0.80 to 0.89)* 0.96 (0.93 to 0.98)* 1.14 (1.05 to 1.24) 0.71 (0.62 to 0.82)
CIN3+ 9 0.86 (0.76 to 0.98)* 0.97 (0.95 to 0.99)* 0.65 (0.57 to 0.78)
PCR CIN2+ 17 0.99 (0.97 to 1.02) 0.98 (0.97 to 0.99)* 1.00 (0.94 to 1.06) 0.97 (0.90 to 1.04)
CIN3+ 8 0.99 (0.96 to 1.02) 0.98 (0.97 to 0.99)* 0.90 (0.78 to 1.05)

PPV=positive predictive value; CIN2+=cervical intraepithelial neoplasia of grade 2 or worse; CIN3+=cervical intraepithelial neoplasia of grade 3 or worse.

*

Statistically significantly different from unity.